Five Prime Therapeutics, Inc.
Investor Relations Department
Two Corporate Dr, Suite 200
South San Francisco, CA 94080
United States

Visit IR website
Sign-up for email alerts

NASDAQ: FPRX [1]	
Last Trade:	34.42
Trade Time:	4:00 PM ET Tuesday, April 25, 2017
Change:	0.36 ↑ (1.057%)
Day Range	34.15 - 35.13
52-Week Range	31.79 - 60.98
Volume	453,050
Market Cap. ($M)	990.263
Shares Out (M)	28.770

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

… (more)

Stock Performance

Press Releases [View all]

Thursday, April 20, 2017
Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting

Thursday, April 20, 2017
Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4

Monday, April 10, 2017
Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)

Monday, April 3, 2017
Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting

Monday, April 3, 2017
Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting

Events [View all]

Thursday, May 4, 2017 4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q1 Quarterly Earnings Call

Financials [View all]

Fourth Quarter Financial Results

Friday, February 24, 2017
Annual Report (10-K)

Friday, March 31, 2017
Definitive Proxy Statement

Friday, November 4, 2016
Quarterly Report (10-Q)

Friday, August 5, 2016
Quarterly Report (10-Q)

Friday, May 6, 2016
Quarterly Report (10-Q)

Nasdaq